Many people believe that urinary tract infections (UTIs) and incontinence are more common in women, but they can also affect ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

A football fan who has stage four prostate cancer is backing a campaign for sanitary bins to be put in men's toilets at ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

[7] Among men with both DO and BOO that did not improve on alpha-blocker monotherapy, 73% did show symptomatic improvement after 3 months of tolterodine treatment. Urge urinary incontinence ...

Driven by a combination of demographic, social, and technological factors, the disposable incontinence products industry is ...

The Fourth International Consultation on Incontinence recently redefined the signs, symptoms, urodynamic observations and conditions associated with lower urinary tract symptoms and urodynamic ...

Additionally, the average daily number of urge urinary incontinence episodes was lower ... of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated ...